From: Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
Overall response
Sum
Response
Non-response
Early tumor shrinkage
Yes
17
6
23
No
13
67
80
30
73
103